Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)

類似資料

• Local Recurrence Rates are Low in High-Risk Neoadjuvant Breast Cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657)
  著者:: Cureton, Elizabeth L., 等
  出版事項: (2014)
• Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657
  著者:: Esserman, Laura J., 等
  出版事項: (2012)
• Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
  著者:: Esserman, Laura J., 等
  出版事項: (2011)
• Receptor Activator of Nuclear Factor Kappa B (RANK) Expression in Primary Breast Cancer Correlates with Recurrence Free Survival and Development of Bone Metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657)
  著者:: Vidula, Neelima, 等
  出版事項: (2017)
• Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)
  著者:: Lin, Cheryl, 等
  出版事項: (2011)